Opinion|Videos|November 29, 2024
KEYNOTE-361 Highlights: Challenges and Insights
Author(s)Thomas Powles MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MD, discusses how the KEYNOTE-361 trial failed because of the trial’s design. Data show that the maintenance phase of the trial is what was driving the benefit and that the longest survival with this trial was 17 months with both pembrolizumab and chemotherapy treatment rather than just chemotherapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
Camrelizumab Plus Nab-Paclitaxel Yields Efficacy in Previously Treated Advanced Urothelial Carcinoma
Later-line camrelizumab plus nab-paclitaxel produced durable responses in platinum-treated advanced urothelial carcinoma.
First-line tislelizumab plus gemcitabine produced durable responses in platinum-ineligible locally advanced or metastatic urothelial carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
The OncFive: Top Oncology Articles for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5